Utilization of Prostate Health Index in prediction of prostate cancer aggressiveness

Česká verze

Authors: P. Brož ^1,4; O. Dolejšová ²; R. Fuchsová ¹; O. Topolčan ¹; J. Racek ⁴; H. Sedláčková ²; O. Hes ³; V. Eret ²; L. Pecen ¹; M. Hora ²; R. Kučera ¹
Authors place of work: Oddělení imunochemické diagnostiky FN a LF v Plzni, Univerzita Karlova v Praze ¹; Urologická klinika FN Plzeň ²; Šiklův ústav patologie FN a LF v Plzni, Univerzita Karlova v Praze ³; Ústav klinické biochemie a hematologie FN a LF v Plzni, Univerzita Karlova v Praze ⁴
Published in the journal: Klin. Biochem. Metab., 27, 2019, No. 1, p. 9-15

Summary

Aim: To assess the Prostate Health Index (PHI) as a marker of tumor aggressiveness in comparison with prostate biopsy and postoperative histology.

Methods: Our cohort consisted of 474 patients indicated for radical prostatectomy with preoperative measurements of total prostate-specific antigen, free prostate-specific antigen, [-2]proPSA, calculated %freePSA, and PHI. The Gleason score was determined during biopsy and after radical prostatectomy. Using the Gleason score, we divided the group of patients into the 2 subgroups: Gleason score 6 and Gleason score ≥7. This division was performed according to the biopsy Gleason score and according to the postoperative Gleason score. We compared total prostate specific antigen, [-2]proPSA, %freePSA, and PHI in the subgroups Gleason score 6 and Gleason score ≥7 after biopsy and the definitive score.

Results: Of the calculated biopsy, Gleason score 6 and Gleason score ≥7 subgroups, [-2]proPSA, PHI and PSA (p < 0.0001, p < 0.0001 and p = 0.0012) were statistically significant. In case of %freePSA statistically significant differences were not present (p = 0.9306). Of the definitive Gleason score 6 and Gleason score ≥7 subgroups, PHI, [-2]proPSA, %freePSA, and PSA (p < 0.0001, p < 0.0001, p < 0.0001, and p = 0.0012) were statistically significant. The best area under the curve value (0.7649) was achieved by PHI when the subgroups were established according to the postoperative Gleason score.

Conclusion: PHI is the best of tested markers for the categorization of Gleason score 6 and Gleason score ≥7 tumors. Implementation of PHI can be useful in the management of patients with prostate cancer. PHI can be a helpful marker for indication of active surveillance or radical prostatectomy, or simplify the decision of whether to perform nerve-sparing radical prostatectomy.

Keywords:

Prostate Health Index – prostate-specific antigen – prostate cancer – Gleason score – prostate biopsy – Radical prostatectomy

Zdroje

1. Fuchsova, R., Topolcan, O., Windrichova, J., et al. PHI in the Early Detection of Prostate Cancer. Anticancer. Res. 2015, 35(9), p. 4855–7.

2. Wilt, T. J., Jones, K. M., Barry, M. J., et al. Follow-up of Prostatectomy versus Observation for Early Prostate Cancer. N Enql. J Med., 2017, 377(2), p. 132-142. doi: 10.1056/NEJMoa1615869.

3. Maxeiner, A., Kilic, E., Matalon, J., et al. The prostate health index PHI predicts oncological outcome and biochemical recurrence after radical prostatectomy - analysis in 437 patients. Oncotarget 2017. doi: 10.18632/oncotarget.17476. [Epub ahead of print].

4. Epstein, J. I., Egevad, L., Amin, M. B., et al. The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System. Am J Surg. Pathol., 2016, 40(2), p. 244-52. doi: 10.1097/PAS.0000000000000530.

5. Epstein, J. I., Zelefsky, M. J., Sjoberg, D. D., et al. A Contemporary Prostate Cancer Grading System: A Validated Alternative to the Gleason Score. Eur Urol., 2016, 69(3), p. 428–35.

6. Fossati, N., Buffi, N. M., Haese, A. et al. Preoperative Prostate-specific Antigen Isoform p2PSA and Its Derivatives, %p2PSA and Prostate Health Index, Predict Pathologic Outcomes in Patients Undergoing Radical Prostatectomy for Prostate Cancer: Results from a Multicentric European Prospective Study. Eur. Urol., 2016, 68(1), p. 132–8.

7. Kulac, I., Haffner, M. C., Yegnasubramanian, S., Epstein, J. I., De Marzo, A. M. Should Gleason 6 be labeled as cancer? Curr. Opin. Urol., 2015, 25(3), p. 238–45.

8. Carter, H. B., Partin, A. W., Walsh, P. C., et al. Gleason Score 6 Adenocarcinoma: Should It Be Labeled As Cancer? J Clin. Oncol., 2012, 30(35), p. 4294–6.

9. Pivovarcikova, K., Branzovsky, J., Bauleth, K., et al. Radical prostatectomy – analysis of 191 cases examined using whole-mount section method Czech Urol., 2014, 18(1), p. 26–32.

10. DeLong, E. R., DeLong, D. M., Clarke-Pearson, D. L. Comparing the Areas under Two or More Correlated Receiver Operating Characteristic Curves: A Nonparametric Approach. Biometrics, 1988, 44(3), p. 837–45.

11. Lepor, A., Catalona, W. J., Loeb, S. The Prostate Health Index: Its Utility in Prostate Cancer Detection. Urol. Clin. North. Am., 2016, 43(1), p. 1-6. doi:10.1016/j.ucl.2015.08.001.

12. Sanda, M., Wei, J., Broyles, D., Shin, S., Partin, A., Klee, G., et al. (2013) Evaluation of the Prostate Health Index (PHI) for improving prostate cancer detection and identification of clinically significant prostate cancer in the 4 to 10 ng/mL PSA range. In: Proceedings of American Urological Association Annual Meeting, San Diego.

13. Lazzeri, M., Haese, A., Abrate, A., et al. Clinical performance of serum prostate-specific antigen isoform
[-2]proPSA (p2PSA) and its derivatives, %p2PSA and the prostate health index (PHI), in men with a family history of prostate cancer: results from a multicentre European study, the PROMEtheuS project. BJU Int., 2013, 112(3), p. 313–21.

14. Wang, W., Wang, M., Wang, L. et al. Diagnostic abi-lity of %p2PSA and prostate health index for aggressive prostate cancer: a meta-analysis. Sci Rep., 2014, 4, p. 5012.

15. Heidenreich, A., Aus, G., Bolla, M., Joniau, S. et al. European Association of Urology. EAU guidelines on prostate cancer. Eur Urol., 2008, 53(1), p. 68-80.

16. Toren, P., Alibhai, S. M., Matthew, A., et al The effect of nerve-sparing surgery on patient-reported continence post-radical prostatectomy. Can. Urol. Assoc. J., 2009, 3(6), p. 465-70.

17. Friedersdorff, F., Groß, B., Maxeiner, A., et al. Does the Prostate Health Index Depend on Tumor Volume?—A Study on 196 Patients after Radical Prostatectomy. Int. J Mol. Sci., 2017, 18(3), p. 488.

18. Beauval, J. B., Cabarrou, B., Gandaglia, G., et al. External validation of a nomogram for identification of pathologically favorable disease in intermediate risk prostate cancer patients. Prostate. 2017, 77(8), p. 928-933. doi: 10.1002/pros.23348.

19. Gandaglia, G., Schiffmann, J., Schlomm, T., et al. Identification of pathologically favorable disease in intermediate-risk prostate cancer patients: Implications for active surveillance candidates. Prostate. 2015, 75(13), p. 1484-91. doi: 10.1002/pros.23040.

20. Hendriks, R. J., van Oort, I. M., Schalken, J. A. Blood-based and urinary prostate cancer biomarkers: a review and comparison of novel biomarkers for detection and treatment decisions. Prostate Cancer Prostatic Dis., 2017, 20(1), p. 12–9.

21. NCCN Guidelines Version 1.2018, Prostate Cancer Early Detection, National Comprehensive Cancer Network, 2018.

22. Lamy, P. J., Allory, Y., Gauchez, A. S., et al. Prognostic Biomarkers Used for Localised Prostate Cancer Management: A Systematic Review. Eur. Urol. Focus, 2017, 7(17), Ahead of print